Investing.com101d agobullish
Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalystsInvesting.com -- Pfizer shares may have found a more balanced risk-reward profile after a sharp decline this year, prompting RBC Capital Markets to upgrade the drugmaker to Sector Perform from Underperform while maintaining its $25 price target. The brokerage said the stock's roughly 11% pullback from its 2026 highs has brought valuation in line with its expectations, reducing the downside risks it had previously highlighted.